Brainstorm Cell Therapeutics (FRA:GHDN) Cash-to-Debt : 0.70 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Brainstorm Cell Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Brainstorm Cell Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.70.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Brainstorm Cell Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Brainstorm Cell Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:GHDN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: 14.14 Max: No Debt
Current: 0.7

During the past 13 years, Brainstorm Cell Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.23. And the median was 14.14.

FRA:GHDN's Cash-to-Debt is ranked worse than
76.59% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs FRA:GHDN: 0.70

Brainstorm Cell Therapeutics Cash-to-Debt Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Brainstorm Cell Therapeutics Cash-to-Debt Chart

Brainstorm Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.24

5.81

4.35

0.73

1.02

Brainstorm Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.61	0.23	0.49	1.02	0.70

Competitive Comparison of Brainstorm Cell Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Cash-to-Debt falls into.

Brainstorm Cell Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Brainstorm Cell Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.192	/	(0.553	+	0.616)
	=	1.02

Brainstorm Cell Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.717	/	(0.541	+	0.49)
	=	0.70

Brainstorm Cell Therapeutics (FRA:GHDN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Brainstorm Cell Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (FRA:GHDN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BCLI:USA GHDN:Germany

Address

1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019

Website

https://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (FRA:GHDN) Headlines

No Headlines